GSI Treatment Preserves Protein Synthesis in C2C12 Myotubes

Cells. 2021 Jul 15;10(7):1786. doi: 10.3390/cells10071786.

Abstract

It has been demonstrated that inhibiting Notch signaling through γ-secretase inhibitor (GSI) treatment increases myogenesis, AKT/mTOR signaling, and muscle protein synthesis (MPS) in C2C12 myotubes. The purpose of this study was to determine if GSI-mediated effects on myogenesis and MPS are dependent on AKT/mTOR signaling. C2C12 cells were assessed for indices of myotube formation, anabolic signaling, and MPS following GSI treatment in combination with rapamycin and API-1, inhibitors of mTOR and AKT, respectively. GSI treatment increased several indices of myotube fusion and MPS in C2C12 myotubes. GSI-mediated effects on myotube formation and fusion were completely negated by treatment with rapamycin and API-1. Meanwhile, GSI treatment was able to rescue MPS in C2C12 myotubes exposed to rapamycin or rapamycin combined with API-1. Examination of protein expression revealed that GSI treatment was able to rescue pGSK3β Ser9 despite AKT inhibition by API-1. These findings demonstrate that GSI treatment is able to rescue MPS independent of AKT/mTOR signaling, possibly via GSK3β modulation.

Keywords: AKT; GSI; mTOR; muscle protein synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / drug effects*
  • Amyloid Precursor Protein Secretases / metabolism
  • Animals
  • Cell Differentiation / drug effects
  • Mice
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism
  • Muscle Proteins / metabolism
  • Muscle, Skeletal / metabolism
  • Myoblasts / drug effects
  • Myoblasts / metabolism
  • Protein Biosynthesis / drug effects*
  • Protein Synthesis Inhibitors / metabolism
  • Protein Synthesis Inhibitors / pharmacology*
  • Signal Transduction / drug effects

Substances

  • Muscle Proteins
  • Protein Synthesis Inhibitors
  • Amyloid Precursor Protein Secretases